Advanced Search

 

Study ID Status Title Patient Level Data
DAN106587 Completed A placebo controlled, single blind, randomised study investigating the safety, tolerability and Pharmacokinetics of repeated oral doses of GSK598809 in healthy male and female volunteers for 28 days.
DAN106593 Completed A randomized, double-bind, placebo controlled, two-way cross-over study to assess the effects of a single dose of GSK598809, a Selective DRD3 Antagonist, in Modulating Nicotine Reward Study Listed on ClinicalStudyDataRequest.com
DAN107606 Completed A placebo-controlled, single-blind, randomised, human volunteer study investigating the tolerability and pharmacokinetics of escalating single oral doses of GSK598809 in smokers
DAN111282 Completed A placebo-controlled, single-blind, randomised, human volunteer study investigating the tolerability and pharmacokinetics of escalating single oral doses (75mg and above) of GSK598809 in otherwise healthy volunteers.
DAN111283 Completed An open label, randomised, single dose, three-way crossover study to investigate the relative bioavailability of a 100mg capsule compared to four 25mg GSK598809 capsules and the effect of food on the pharmacokinetics of the 100mg capsule in healthy male and female volunteers.
DB1111509 Completed A single centre, randomised, placebo-controlled, four-way cross over study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705 and GW642444 as monotherapies and in combination in healthy subjects. Study Listed on ClinicalStudyDataRequest.com
DB1111581 Completed A multicenter, randomized, double-blind, placebo-controlled, parallel-group, 4-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat inhaled doses of the combination of GSK233705 and GW642444 administered once-daily in subjects with COPD Study Listed on ClinicalStudyDataRequest.com
DBU107640 Completed A First Time in Human, Blinded, Randomised, Placebo-Controlled, two-cohort Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single Oral Escalating Doses of GSK618334 in Healthy Male Volunteers
DENB4016 Completed A multicentre, randomised, double-blind, double-dummy, parallel group clinical trial to determine the clinical equivalence between fluticasone propionate 400?g/daily via the DiskusTM and budesonide 800?g/daily via the TurbuhalerTM administered for 5 months in pre-pubescent children aged 4 to 12 ...
DIX110434 Completed A Single-Center, Non-Randomized, Open-Label, Comparative Study to Assess the Utility of Novel Technologies and Biomarkers as Methods for Measuring Human Pharmacodynamic Response to 8 Weeks of Administration of Rosiglitazone Maleate 4mg BID in Healthy Normal or Overweight Controls, Healthy Obese Subjects and Subjects with Type 2 Diabetes Mellitus (T2DM) Study Listed on ClinicalStudyDataRequest.com
DPB100925 Completed A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus followed by a 12-week Active Treatment Extension Study Listed on ClinicalStudyDataRequest.com
DRI2440 - Rembrandt Completed A Multicentre, Randomized, Double-Blind, Dose Ranging Study of Org31540/SR90107A in the Initial Treatment of Symptomatic Proximal Deep Vein Thrombosis (DVT)
DRI2643 Completed A multicenter, randomized, parallel, double-blind, dose ranging study of subcutaneous Org31540/SR90107A with an assessor blind, comparative control group of subcutaneous LMWH in the prevention of deep vein thrombosis after elective total hip replacement (Pentathlon).
DRI3196 Completed A multicentre, randomised, dose-ranging study comparing Org31540/SR90107A with heparin as adjunctive therapy to recombinant tissue plasminogen activator and Aspirin in acute myocardial infarction (AMI) (PENTALYSE)
DRI4090 Completed A multicenter, randomized, double-blind, placebo controlled, parallel group, dose response study of subcutaneous Org31540/SR90107A in the prevention of venous thromboembolism after elective total hip replacement surgery.
DRI4757 Completed A multicenter, randomized, double-blind, placebo-controlled, parallel group, dose response study of subcutaneous Org31540/SR90107A in the prevention of venous thromboembolism after elective total knee replacement surgery.
E3870651 Completed A randomised, Two Way Crossover Study to Determine the Time at Which Therapeutic Plasma Concentrations of Paracetamol are Achieved in Two Marketed Formulations
E7411153 Completed An exploratory study to investigate the inflammatory response during a cold sore episode
EFC2441 Completed A multicentre, randomized, double-blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE-DVT)
EFC2442 Completed A multicenter, multinational, randomized, double-blind comparison of subcutaneous Org31540/SR90107A with enoxaparin in the prevention of deep vein thrombosis and symptomatic pulmonary embolism after elective hip replacement or a revision. PENTATHLON 2000
EFC2698 Completed A multicenter, multinational, randomized double-blind comparison study of subcutaneous Org31540/SR90107A versus enoxaparin 40 mg o.d. in the prevention of deep vein thrombosis and symptomatic pulmonary embolism in hip fracture surgery. (PENTHIFRA)
EFC3557 Completed A multicenter, multinational, randomized, double-blind study to compare the efficacy and safety of fondaparinux sodium (Org31540/SR90107A) with dalteparin (Fragmin) in the prevention of venous thromboembolic events in high-risk abdominal surgery (PEGASUS) Study Listed on ClinicalStudyDataRequest.com
EFC4582 Completed A multicenter, multinational, randomized, double-blind study of fondaparinux sodium (Org31540/SR90107A) versus placebo for the prolonged prevention of VTE in hip fracture surgery. (PENTIHFRA PLUS) Study Listed on ClinicalStudyDataRequest.com
EGF 20002 Completed An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects with Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving Herceptin Containing Regimens
EGF10001 Completed A Double Blind, Randomized, Placebo-Controlled, Crossover Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Single Oral Escalating Doses Of GW572016 Ditosylate Monohydrate (Lapatinib) In Healthy Volunteers

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.